Predictive Value of PD-L1 and Other Clinical Factors for Chemoimmunotherapy in Advanced Non-Small-Cell Lung Cancer
We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n = 4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58–0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34–0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55–0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65–0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.
Authors
- Ian C. Marschner (ORCID: https://orcid.org/0000-0002-6225-1572)
- Rachel G. Woodford (ORCID: https://orcid.org/0000-0002-9470-314X)
- Craig R. Lewis (ORCID: https://orcid.org/0000-0001-8734-1702)
- Richard J. Gralla (ORCID: https://orcid.org/0000-0001-7963-3086)
- Michael Millward (ORCID: https://orcid.org/0000-0002-1744-1617)
- Joanna Lee
- Yanni Loh
- Wendy Cooper
- Tony Mok
- James C. H. Yang
- Chee K Lee
- Sally Lord
Publication Details
- Journal
- Figshare
- Published
- 2026-11-12
- DOI
- https://doi.org/10.6084/m9.figshare.34997995
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00